![]() |
市场调查报告书
商品编码
1355822
兽医自体免疫疾病治疗市场 - 按治疗(皮质类固醇、硫唑嘌呤)、疾病(甲状腺功能减退症、天疱疮)、动物类型(伴侣、牲畜)、配销通路(医院、诊所)、全球预测( 2023 - 2032)Veterinary Autoimmune Disease Therapeutics Market - By Therapy, Disease, Animal Type, Distribution Channel, Global Forecast (2023 - 2032) |
2023年至2032年,全球兽医自体免疫疾病治疗市场的复合年增长率将超过5.3%。包括狗和猫在内的动物自体免疫疾病发生率的上升推动了对有效治疗的需求。宠物饲养量的增加以及人类与宠物之间联繫的加深有助于人们愿意投资先进的治疗方法。
例如,根据《富比士》2023 年6 月的一份报告,美国宠物拥有率达到66%,覆盖8,690 万个家庭,比1988 年的56% 有所增加。这些统计数据证明了宠物在人们生活中的持久重要性。对许多人来说,宠物提供陪伴和情感支持,85% 的狗主人和 76% 的猫主人认为他们毛茸茸的朋友是不可或缺的家庭成员。兽医学和诊断学的进步正在扩大治疗选择。此外,人们对动物自体免疫疾病的认识不断提高,促进了兽医自体免疫疾病治疗市场的成长。
整个兽医自体免疫疾病治疗市场根据治疗、疾病和地区进行分类。
硫唑嘌呤细分市场将在 2023 年至 2032 年间经历重大发展。硫唑嘌呤是一种重要的免疫抑制药物,用于治疗动物自体免疫疾病。其在控制过度免疫反应和减轻发炎和器官损伤等症状方面的功效使其成为兽医自体免疫疾病治疗中广受欢迎的治疗选择,极大地满足了兽医自身免疫疾病治疗的市场需求。
从 2023 年到 2032 年,天疱疮疾病领域的复合年增长率将值得称讚。天疱疮是一种影响宠物的自体免疫疾病,会导致皮肤和黏膜病变疼痛。需要兽医自体免疫疾病治疗药物,包括皮质类固醇和免疫抑制剂等药物来控制和缓解天疱疮症状,改善受影响动物的生活品质并推动兽医自体免疫疾病治疗市场收入。
2023年至2032年,欧洲兽医自体免疫疾病治疗市场将呈现可观的复合年增长率。该地区对宠物根深蒂固的喜爱、严格的动物福利标准和先进的兽医护理基础设施推动了对自身免疫性疾病治疗的需求。各国加强遏制虐待动物,支持了该地区市场的成长。例如,根据2022年6月消息,法国立法者于2021年11月通过了《对待动物法》修正案。根据该修正案,从2024年开始,宠物商店将被禁止展示和销售狗和猫。
此外,公众将不再被允许进行涉及猫狗的线上交易。该法规旨在解决不断升级的遗弃宠物问题,该问题在 COVID-19 大流行期间有所增加。随着人们对宠物健康和自体免疫疾病的认识不断提高,欧洲仍然是兽医自体免疫疾病治疗的重要市场,支持整个非洲大陆深受喜爱的伴侣动物的福祉。
Global Veterinary Autoimmune Disease Therapeutics Market will witness over 5.3% CAGR between 2023 and 2032. The rising incidence of autoimmune diseases in animals, including dogs and cats, propels the demand for effective treatments. Increasing pet ownership and the deepening bond between humans and their pets contribute to a willingness to invest in advanced treatments.
For instance, according to a Forbes report from June 2023, pet ownership in the United States reached 66%, encompassing 86.9 million households-an increase from 56% recorded in 1988. These statistics prove the enduring significance of pets in people's lives. For many, pets provide companionship and emotional support, with 85% of dog owners and 76% of cat owners considering their furry friends as integral family members. Advancements in veterinary medicine and diagnostics are expanding treatment options. Additionally, the growing awareness of autoimmune conditions in animals fosters veterinary autoimmune disease therapeutics market growth.
The overall Veterinary Autoimmune Disease Therapeutics Market is classified based on therapy, disease, and region.
The azathioprine segment will undergo significant development from 2023 to 2032. Azathioprine is a crucial immunosuppressive drug used to manage autoimmune disorders in animals. Its efficacy in controlling excessive immune responses and alleviating symptoms like inflammation and organ damage makes it a sought-after treatment option in veterinary autoimmune disease therapeutics, contributing significantly to veterinary autoimmune disease therapeutics market demand.
The pemphigus disease segment will register a commendable CAGR from 2023 to 2032. Pemphigus is an autoimmune condition that affects pets, leading to painful skin and mucous membrane lesions. Veterinary autoimmune disease therapeutics, including medications like corticosteroids and immunosuppressants, are in demand to manage and alleviate the symptoms of pemphigus, improving the quality of life for affected animals and driving veterinary autoimmune disease therapeutics market revenue.
Europe veterinary autoimmune disease therapeutics market will showcase an appreciable CAGR from 2023 to 2032. The region's deep-rooted affection for pets, stringent animal welfare standards, and advanced veterinary care infrastructure drive the need for autoimmune disease therapeutics. Increasing efforts from countries to curb the mistreatment of animals support market growth in the region. For instance, according to news from June 2022, French lawmakers passed an amendment to the Act on the Treatment of Animals in November 2021. According to this amendment, pet stores will be prohibited from exhibiting and selling dogs and cats starting in 2024.
In addition, the public will no longer be permitted to conduct online transactions involving dogs and cats. The regulation intends to combat the escalating issue of pet abandonment, which witnessed an increase during the COVID-19 pandemic. With increasing awareness of pet health and autoimmune conditions, Europe remains a significant market for veterinary autoimmune disease treatments, supporting the well-being of beloved companion animals across the continent.